Format

Send to

Choose Destination
Curr Neurol Neurosci Rep. 2010 Jul;10(4):259-66. doi: 10.1007/s11910-010-0111-9.

Immunotherapy approaches for malignant glioma from 2007 to 2009.

Author information

1
Duke Brain Tumor Immunotherapy Program, Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, DUMC 3050, Sands Research Building, Durham, NC 27710, USA. laura.a.johnson@duke.edu

Abstract

Malignant glioma is a deadly disease for which there have been few therapeutic advances over the past century. Although previous treatments were largely unsuccessful, glioma may be an ideal target for immune-based therapy. Recently, translational research led to several clinical trials based on tumor immunotherapy to treat patients with malignant glioma. Here we review 17 recent glioma immunotherapy clinical trials, published over the past 3 years. Various approaches were used, including passive transfer of naked and radiolabeled antibodies, tumor antigen-specific peptide immunization, and the use of patient tumor cells with or without dendritic cells as vaccines. We compare and discuss the current state of the art of clinical immunotherapy treatment, as well as its limited successes, pitfalls, and future potential.

PMID:
20424975
PMCID:
PMC3412398
DOI:
10.1007/s11910-010-0111-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center